NICE refuses AstraZeneca breast cancer drug on NHS

November 14, 2017

Maria Leadbeater, clinical nurse specialist at Breast Cancer Care, explained the charity's disappointment and feared it would shrink an already small number of treatment options. ???The decision by NICE not to recommend the routine prescription of fulvestrant by the NHS for post-menopausal women with locally advanced or secondary breast cancer is disappointing news for patients and their families,??? she said.

???While we recognise that drug decisions must be based, to some degree, on cost effectiveness, this approach can fail to take into account what is important for the patient. Treatment options for people living with secondary breast cancer are limited, so any drugs which delay time to progression are especially valuable. We do, however, welcome the acknowledgement of the importance of additional treatment options for this patient group.???

Those women currently being treated with fulvestrant will be able to remain on the drug until they or their consultant considers it appropriate to stop.

AstraZeneca said Faslodex was already reimbursed in over 50 markets around the world and the company would continue to work with local health authorities in Britain for continued access to the medicine, where possible. The company had been hoping for a change of heart after NICE reached a preliminary decision against Faslodex in August.

Worldwide sales of Faslodex totalled US$397 million in the first nine months of 2011.